AXT (AXTI) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $19.4 million, down from $25.1 million in Q4 2024 and $22.7 million in Q1 2024, reflecting challenging market conditions and trade restrictions.

• Gross margin turned negative at -6.4% GAAP and -6.1% non-GAAP, primarily due to yield issues, product mix, and under-absorbed overhead.

• Net loss widened to $8.8 million GAAP ($0.20/share) and $8.2 million non-GAAP ($0.19/share), compared to $5.1 million and $4.3 million losses in Q4 2024.

• Cash and investments increased to $38.2 million as of March 31, 2025, with inventory reduced to $80.4 million.

• Management is prioritizing operational improvements, especially in gallium arsenide substrate production, and expects margin recovery through 2025.

Financial highlights

• Indium Phosphide revenue was $3.8 million, Gallium Arsenide $6.7 million, Germanium $0.6 million, and JV raw materials $8.3 million.

• Substrate revenue fell 34.4% to $11.1 million, while raw materials revenue rose 43% to $8.3 million year-over-year.

• GAAP gross margin dropped to -6.4% from 17.6% in Q4 2024 and 26.9% in Q1 2024; non-GAAP gross margin was -6.1%.

• Operating expenses decreased to $9.0 million in Q1 2025.

• Cash and cash equivalents rose to $31.6 million at March 31, 2025, with restricted cash at $6.6 million.

Outlook and guidance

• Q2 2025 revenue expected between $20.0–$22.0 million, excluding Indium Phosphide shipments outside China.

• Gross margin targeted to recover to ~10% in Q2, with further improvement expected in the second half of 2025.

• Non-GAAP net loss projected at $0.12–$0.14 per share for Q2.

• Several million dollars of Indium Phosphide backlog ready to ship once permits are secured, likely in Q3.

• Management expects continued volatility due to escalating tariffs, export controls, and uncertain timing for export permits.